arrow_back Trending Legislation
Share share

Improved Access to Plasma-Derived Medicines: New Discount Rules

This act introduces gradual changes to the discount program for plasma-derived medicines, which are crucial for many patients. The goal is to ensure these life-saving drugs remain accessible while adjusting their funding rules over time. Citizens using these medications can expect more stable access to their therapies.
Key points
Gradual implementation of new discount rules for plasma-derived products starting in 2026.
Changes apply to drugs derived from human whole blood or plasma, marketed as of August 16, 2022.
The discount percentage will change annually, reaching 90% for those below the out-of-pocket threshold and 80% for those above by 2032.
Exceptions to the new rules include drugs for low-income beneficiaries and those from specified small manufacturers.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Introduced
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
PLASMA Act
Print number: S 694
Sponsor: Sen. Tillis, Thomas [R-NC]
Process start date: 2025-02-24
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Improved Access to Plasma-Derived Medicines: New Discount Rules

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is S 694.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2025-02-24.

What are the main provisions?

Key points include:

  • Gradual implementation of new discount rules for plasma-derived products starting in 2026.
  • Changes apply to drugs derived from human whole blood or plasma, marketed as of August 16, 2022.
  • The discount percentage will change annually, reaching 90% for those below the out-of-pocket threshold and 80% for those above by 2032.
  • Exceptions to the new rules include drugs for low-income beneficiaries and those from specified small manufacturers.

What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Tillis, Thomas [R-NC].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-23.

Analysis and Potential Impact of S 694

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health Benefits